DYNE-251: Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy

When:
November 3, 2022 1:00PM

Join us for a Community Webinar on Thursday, November 3, 2022 as we welcome Ashish Dugar, PhD, MBA and Molly White from Dyne Therapeutics to provide an overview on their Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

DYNE-251: Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy
Thursday, November 3, 2022 | 1:00PM – 2:00PM EST

Ashish Dugar, PhD, MBA

Guest Speaker

Dr. Ashish Dugar, Senior Vice President and Global Head of Medical Affairs, brings to Dyne over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Previously, he led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Dr. Dugar joined Intra-Cellular Therapies following his tenure at Roche, where he was global head of clinical development science and innovation and global head of the external development group, including work in oligonucleotides. Previously, he spent 13 years at Pfizer Inc. in various roles, most recently serving as vice president, global head of clinical development and medical affairs of the biosimilars business unit.

Dr. Dugar began his career at the National Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health. Dr. Dugar earned an MBA from The Pennsylvania State University and a Ph.D. in pharmacology from The Pennsylvania State University College of Medicine.

Molly White

Guest Speaker

Molly White, VP, Global Head of Patient Advocacy and KOL Engagement, brings extensive experience in patient advocacy and community engagement to her role at Dyne. She previously served as chief executive officer of the Myotonic Dystrophy Foundation, an organization dedicated to advancing research and enhancing the quality of life of people living with myotonic dystrophy. In that role, she led strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Molly has over 25 years of leadership-level experience building, implementing and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She has created partnerships with a range of governmental, nonprofit and private sector stakeholders to launch initiatives targeting key national issues such as childhood obesity prevention and components of healthcare reform. She received her M.A. from the University of Iowa.

Community Webinar Series - Better preparing for challenges in Duchenne

Our Community Webinar Series is focused on ensuring that our Duchenne community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.

No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.